*1.Please list your first name, last name, and email:(Required.)

First name:

Last name:

Email:

*2.What is your specialty?(Required.)

*3.How many patients with pancreatic cancer do you treat each week?(Required.)

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

*4.What percent of pancreatic adenocarcinomas harbor pathogenic/likely pathogenic BRAF gene alterations?(Required.)

0.5%

1.5%

3.5%

5%

*5.Which pancreatic cancer subgroup is more likely to harbor BRAF gene alterations?(Required.)

Ductal adenocarcinomas

Acinar cell carcinomas

Neuroendocrine cancers

*6.Of the following BRAF altered molecular subgroups, which is UNLIKELY to response to raf +/- mek inhibitors?(Required.)

Exon 15 (e.g. BRAF V600E)

Exon 11 (e.g. BRAF N486_P490del)

Raf fusions

Kinase dead raf mutations